Xu Qin, Tao Limei, Wang Li, Li Bo, Tang Zouying, Lin Na, Ge Jing, Zhuan Li
Department of Reproductive Medicine, The First People's Hospital of Yunnan Province, Kunming, 650000, Yunnan, China.
Department of Pathology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.
BMC Pregnancy Childbirth. 2025 Aug 8;25(1):829. doi: 10.1186/s12884-025-07918-0.
For patients with recurrent serous borderline ovarian tumors (BOT) who have undergone unilateral salpingo-oophorectomy, there is a risk of reduced or even lost ovarian reserve after the second surgery; therefore, fertility preservation (FP) prior to re-operation in patients of childbearing age is challenging, and has attracted increasing attention. Here, we discuss the multidisciplinary whole-process management of a patient with recurrent serous BOT, from embryo cryopreservation (EC) before re-fertility-sparing surgery (re-FSS) to successful delivery.
We describe the treatment of a 28-year-old married, nulliparous female with recurrent serous BOT who requested FP. The patient underwent right salpingo-oophorectomy in July 2020 for serous BOT. In March 2023, B-ultrasound indicated BOT recurrence, and she underwent a second operation. After a multidisciplinary discussion and information on the risks, the patient strongly requested EC. We used letrozole (LE) combined with an antagonist for ovarian stimulation; 16 eggs were obtained, 15 eggs were MII, four embryos on the 3rd day and one blastocyst was formed and cryopreserved. One month later, laparoscopic cystectomy was performed, and pathological examination revealed serous BOT. Three months after the operation, resuscitation and transplantation of one blastocyst did not result in pregnancy through the natural cycle (NC), followed by resuscitation and transfer of two embryos on day 3 through hormone replacement therapy (HRT), which resulted in a successful pregnancy and live healthy male birth. No recurrence was reported at 19 months after re-FSS.
This case highlights the key points of comprehensive multidisciplinary management from the discovery of BOT recurrence, multidisciplinary team (MDT) consultation, ovarian stimulation (OS), egg retrieval, EC, re-FSS, frozen embryo transfer (FET), to delivery. Re-FSS is safe and effective for patients with recurrent serous BOT and strong fertility requirements, and EC before re-FSS is feasible.
对于接受过单侧输卵管卵巢切除术的复发性浆液性交界性卵巢肿瘤(BOT)患者,二次手术后存在卵巢储备功能降低甚至丧失的风险;因此,对育龄期患者在再次手术前进行生育力保存(FP)具有挑战性,且已引起越来越多的关注。在此,我们讨论了一名复发性浆液性BOT患者的多学科全过程管理,从再次保留生育功能手术(re-FSS)前的胚胎冷冻保存(EC)到成功分娩。
我们描述了一名28岁已婚未育、患有复发性浆液性BOT且要求保留生育功能的女性的治疗情况。该患者于2020年7月因浆液性BOT接受了右侧输卵管卵巢切除术。2023年3月,B超显示BOT复发,她接受了二次手术。经过多学科讨论并告知风险后,患者强烈要求进行胚胎冷冻保存。我们使用来曲唑(LE)联合拮抗剂进行卵巢刺激;获得了16枚卵子,15枚卵子为MII期,第3天形成4个胚胎,1个囊胚形成并冷冻保存。1个月后,进行了腹腔镜囊肿切除术,病理检查显示为浆液性BOT。术后3个月,1枚囊胚复苏移植,自然周期(NC)未妊娠,随后通过激素替代疗法(HRT)在第3天复苏并移植2枚胚胎,成功妊娠并分娩出一名健康男婴。re-FSS术后19个月未报告复发。
本病例突出了从发现BOT复发、多学科团队(MDT)会诊、卵巢刺激(OS)、取卵、胚胎冷冻保存、re-FSS、冷冻胚胎移植(FET)到分娩的综合多学科管理的关键点。re-FSS对有复发性浆液性BOT且有强烈生育需求的患者是安全有效的,re-FSS前进行胚胎冷冻保存是可行的。